Perrigo price target raised to $39 from $35 at Piper Sandler

Piper Sandler raised the firm’s price target on Perrigo to $39 from $35 and keeps an Overweight rating on the shares. The firm notes personal care spending looked to be getting progressively healthier in March, nicely rounding out Q1 with little surprises but showing signals of heavier allergy uptake that could provide some upside into April. Piper is still seeing the strongest performance, however, in OTC Private Label self-care products, benefiting Perrigo.